RATIONALE: Positive modulators of the benzodiazepine/GABA(A) receptor complex can heighten aggressive behavior; the GABA(A)/alpha(1) subunit may play a critical role in benzodiazepine-modulated aggressive behavior. OBJECTIVE: The carboline derivatives, beta-CCt and 3-PBC, antagonists with preferential action at the GABA(A) receptors with alpha(1) subunits, may antagonize benzodiazepine-heightened aggression, thus implicating the alpha(1) subunit in heightened aggression. METHODS: The GABA(A) receptor agonist 4,5,6,7-tetrahydroisoxazolo[5,4c]-pyridin-3-ol (THIP) (0.01-3.0 mg/kg), and the benzodiazepine receptor agonists midazolam (0.3-3.0 mg/kg) and triazolam (0.003-3.0 mg/kg) were administered to adult male resident rats to assess the drugs' effects on their aggressive behavior toward an intruder. Then beta-CCt (0.3-10.0 mg/kg) and 3-PBC (0.3-17.0 mg/kg) were each administered in conjunction with midazolam. The salient elements of aggressive and non-aggressive behavior were measured by analyzing video recordings and encoding each behavioral act and posture in terms of its frequency and duration of occurrence. RESULTS: Midazolam significantly increased the duration of aggressive behaviors at 1.0 and 1.7 mg/kg, and triazolam increased attack bite frequency at 0.03 mg/kg, both implicating GABA(A) receptors with benzodiazepine binding sites in aggressive behavior. In the present dose range, THIP did not affect any behaviors. The broad-spectrum benzodiazepine antagonist, flumazenil (1.0 mg/kg), antagonized the aggression-heightening effects of midazolam. beta-CCt (0.3-10.0 mg/kg) and 3-PBC (0.3-17.0 mg/kg) also antagonized the aggression-heightening effects of midazolam (1.0 mg/kg). CONCLUSIONS: These results implicate both the GABA(A) gamma and alpha(1) subunits in benzodiazepine-heightened aggression.
RATIONALE: Positive modulators of the benzodiazepine/GABA(A) receptor complex can heighten aggressive behavior; the GABA(A)/alpha(1) subunit may play a critical role in benzodiazepine-modulated aggressive behavior. OBJECTIVE: The carboline derivatives, beta-CCt and 3-PBC, antagonists with preferential action at the GABA(A) receptors with alpha(1) subunits, may antagonize benzodiazepine-heightened aggression, thus implicating the alpha(1) subunit in heightened aggression. METHODS: The GABA(A) receptor agonist 4,5,6,7-tetrahydroisoxazolo[5,4c]-pyridin-3-ol (THIP) (0.01-3.0 mg/kg), and the benzodiazepine receptor agonists midazolam (0.3-3.0 mg/kg) and triazolam (0.003-3.0 mg/kg) were administered to adult male resident rats to assess the drugs' effects on their aggressive behavior toward an intruder. Then beta-CCt (0.3-10.0 mg/kg) and 3-PBC (0.3-17.0 mg/kg) were each administered in conjunction with midazolam. The salient elements of aggressive and non-aggressive behavior were measured by analyzing video recordings and encoding each behavioral act and posture in terms of its frequency and duration of occurrence. RESULTS:Midazolam significantly increased the duration of aggressive behaviors at 1.0 and 1.7 mg/kg, and triazolam increased attack bite frequency at 0.03 mg/kg, both implicating GABA(A) receptors with benzodiazepine binding sites in aggressive behavior. In the present dose range, THIP did not affect any behaviors. The broad-spectrum benzodiazepine antagonist, flumazenil (1.0 mg/kg), antagonized the aggression-heightening effects of midazolam. beta-CCt (0.3-10.0 mg/kg) and 3-PBC (0.3-17.0 mg/kg) also antagonized the aggression-heightening effects of midazolam (1.0 mg/kg). CONCLUSIONS: These results implicate both the GABA(A) gamma and alpha(1) subunits in benzodiazepine-heightened aggression.
Authors: Snjezana Lelas; James K Rowlett; Roger D Spealman; James M Cook; Chunrong Ma; Xiaoyan Li; Wenyuan Yin Journal: Psychopharmacology (Berl) Date: 2002-03-13 Impact factor: 4.530
Authors: James K Rowlett; Roger D Spealman; Snjezana Lelas; James M Cook; Wenyuan Yin Journal: Psychopharmacology (Berl) Date: 2002-11-06 Impact factor: 4.530
Authors: Emily L Newman; Kiersten S Smith; Aki Takahashi; Adam Chu; Lara S Hwa; Yang Chen; Joseph F DeBold; Uwe Rudolph; Klaus A Miczek Journal: Psychopharmacology (Berl) Date: 2015-09-17 Impact factor: 4.530
Authors: Joshua L Gowin; Charles E Green; Joseph L Alcorn; Alan C Swann; F Gerard Moeller; Scott D Lane Journal: J Psychopharmacol Date: 2011-07-05 Impact factor: 4.153
Authors: Barbara J Kaminski; Michael L Van Linn; James M Cook; Wenyuan Yin; Elise M Weerts Journal: Psychopharmacology (Berl) Date: 2012-12-28 Impact factor: 4.530
Authors: Graziano Pinna; Roberto C Agis-Balboa; Adrian Zhubi; Kinzo Matsumoto; Dennis R Grayson; Erminio Costa; Alessandro Guidotti Journal: Proc Natl Acad Sci U S A Date: 2006-03-06 Impact factor: 11.205
Authors: Brian J Wiltgen; Bill P Godsil; Zechun Peng; Faysal Saab; Harry L June; Michael L Van Linn; James M Cook; Carolyn R Houser; Tom J O'Dell; Gregg E Homanics; Michael S Fanselow Journal: Front Behav Neurosci Date: 2009-10-20 Impact factor: 3.558